Linxis Biopharmaceuticals

LinXis Biopharmaceuticals is pioneering a novel drug delivery platform, Fibrobodies®, to target activated myofibroblasts across multiple fibrotic diseases. The company has a diversified pipeline of Fibrobody®-Drug Conjugates (FDCs) and imaging tracers, with its lead diagnostic program expected to enter pivotal clinical studies in 2027/2028. As a private, pre-revenue company, LinXis is actively engaging in research collaborations and consortium partnerships to advance its pan-fibrosis targeting approach, positioning itself at the intersection of targeted therapeutics and precision diagnostics in a high-unmet-need market.

Fibrobody® platform: engineered protein vectors that selectively target activated myofibroblasts for the delivery of therapeutic payloads (small molecules, siRNA, miRNA inhibitors) or imaging tracers.

LinXis competes in the crowded fibrosis space against companies developing broad-acting anti-fibrotics (e.g., Boehringer Ingelheim, Genentech) and those exploring other targeted approaches, such as antibody-drug conjugates or cell-specific therapies. Its key differentiation is the focus on activated myofibroblast-specific delivery via its proprietary protein vector, a niche with few direct competitors. However, it faces competition from platforms using peptides, antibodies, or other ligands for targeted delivery in fibrosis.